Our data also show that a large number of target genes that are deregulated by ovarian cancer ascites are repressed by inverse PPARβ/δ agonists, with PT-S264 being able to suppress these genes below the basal level observed in the absence of ascites. The gene discussed is PPARD; the disease is ovarian cancer.